News Search Results
Sep 24, 2025, 09:02 ET Immorta Bio Reports Preclinical Activity of Senolytic Immunotherapy SenoVax™ in a Chronic Traumatic Encephalopathy (CTE) Model
explore CTE and other neurodegenerative indications." About Immorta Bio Immorta Bio, Inc. is a longevity-focused biotechnology company developing personalized cellular and immune therapeutics, including SenoVax™ (senolytic immunotherapy) and StemCellRevivify™
More news about: Immorta Bio, Inc.
Sep 24, 2025, 09:00 ET Hood College Receives NSF Grant for Biotechnology Training Program
Biotechnology Training Program to be held in Hood's Bioscience Research and Education Center FREDERICK, Md., Sept. 24, 2025 /PRNewswire/
More news about: Hood College
Sep 24, 2025, 08:30 ET AI and Machine Learning Uses in Neuroscience Drug Discovery, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 24, 2025, 08:30 ET Clinical Data Analysis with Agents: Reliable Automation with Human Oversight, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 24, 2025, 08:00 ET Michroma and CJ CheilJedang Partner to Scale Commercial Production of Natural Colorants
2025 /PRNewswire/ -- Michroma, a biotech pioneer in sustainable natural colorants, and CJ CheilJedang (CJCJ), a global leader in food and biotechnology, today announced a strategic partnership to advance the commercial manufacturing of Michroma's innovative biotech-based colorants. This
More news about: Michroma
Sep 24, 2025, 08:00 ET Tapping LATAM's Untapped Patient Pool for Ophthalmology Trials, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 24, 2025, 08:00 ET Lightstone Ventures Marks Year-to-Date 2025 Milestones for its Innovative Biotech and Medtech Portfolio Companies
Lightstone Ventures today highlighted recent progress across its portfolio of innovative biotechnology and medical device companies, and further enhanced its leadership team. "The Lightstone team, together with our partners at the many innovative
More news about: Lightstone Ventures
Sep 24, 2025, 07:00 ET Marengo to Present a Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Clinical Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoint Blockade
Sept. 24, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation and immunology (I&I), will present a late-breaking
More news about: Marengo Therapeutics
Sep 24, 2025, 07:00 ET Pathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive Director
Dr. Wigginton currently serves as President of Research and Development at Bright Peak Therapeutics, a clinical-stage biotechnology company in the immuno-oncology (I-O) space. In this role, he is charged with leading the advancement of the company's "next-generation" multi-functional
More news about: Pathios Therapeutics
Sep 24, 2025, 07:00 ET SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
Sept. 24, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and BL-M07D1, two distinct clinical programs from its antibody
More news about: SystImmune, Inc.
Sep 24, 2025, 06:00 ET ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
agreement to amend its previously announced Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company. XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) continues to act as structuring agent and intends to provide financing for the
More news about: ESSA Pharma Inc.
Sep 24, 2025, 05:19 ET Global Wearable AI Market to Surpass USD 303.59 Billion by 2035 | Growing at a CAGR 17.6 -- Transforming Healthcare, Lifestyle, and Enterprise Productivity
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 24, 2025, 04:49 ET Fermenta Biotech Limited Certified as a Great Place to Work®
confidential employee feedback, highlighting inclusivity and engagementReinforces Fermenta's positioning as an employer of choice in global biotechnology and nutritionTHANE, India,
More news about: Fermenta Biotech Limited
Sep 24, 2025, 01:29 ET GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities
trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory
More news about: GCCL
Sep 23, 2025, 13:00 ET Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 23, 2025, 12:04 ET Cizzle Bio Champions Cancer Survivors, Early Detection as Sponsor of Prevent Cancer Foundation® 40th Anniversary and Gala
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Cizzle Bio, Inc., a biotechnology company advancing groundbreaking biomarker blood tests for early detection of lung and gastric cancers, proudly sponsored and attended the Prevent
More news about: Cizzle Bio
Sep 23, 2025, 11:01 ET With 8.2% CAGR Chronic Total Occlusion Market Size Surges US$ 4.22 billion by 2031 Amid Rising Cardiovascular Disease Burden | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 23, 2025, 10:30 ET Kidney Dialysis Equipment Market is projected to reach US$27.04 billion by 2031, registering a strong CAGR of 6.8% | Surges Amid Growing Prevalence of Chronic Kidney Disease - The Insight Partners
that by 2029, chronic kidney disease may impact as many as 11.7% of the world's population, according to data released by the National Center for Biotechnology Information. The combined national prevalence of chronic kidney disease in India, which currently accounts
More news about: The Insight Partners
Sep 23, 2025, 10:01 ET With 5% CAGR Paracetamol Market is expected to grow US$15.03 billion by 2031, surging amid the Growing Pharmaceutical Industry | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
[Click here for information about joining the class action] Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. The Company is developing, among other
More news about: Pomerantz LLP
Sep 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
[Click here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Sep 23, 2025, 09:09 ET Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren's Disease Clinical Testing
Md., Sept. 23, 2025 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, today announced it will be initiating clinical evaluation of R-2487 in SjD.
More news about: Rise Therapeutics
Sep 23, 2025, 09:00 ET Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics
Prellis Biologics, Inc., a biotechnology company innovating human antibody discovery through organoid & artificial intelligence enabled technology, announced a multi-target drug discovery
More news about: Prellis Biologics
Sep 23, 2025, 09:00 ET Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge
solutions, and realize those possibilities. Noul has commercialized the world's first AI-powered diagnostic lab, miLab™, through convergence of AI, biotechnology, and compact robotics. The miLab™ Platform is the only solution that fully automates the microscopic diagnostic process—from sample preparation
More news about: Noul
Sep 23, 2025, 08:49 ET Ventoux Biosciences Secures U.S. Patent for Novel Therapy Targeting Dupuytren's Disease and Immune-Fibrotic Disorders
SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Ventoux Biosciences, a biotechnology company developing disease-modifying therapies for fibrotic conditions, today announced the issuance of a U.S. patent covering methods for treating
More news about: Ventoux Biosciences